Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (“Olema” or “the Company”) (NASDAQ: OLMA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Olema is the subject of an Investor’s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema’s competing medication. According to analyst Matthew Biegler, the Roche results "comes with a dent to the thesis that oral SERDs can win in front-line breast cancer." Based on this news, shares of Olema fell by more than 19.6% in morning trading on the same day.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance inve
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (OLMA) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 3/11/26 - Form 144
- 3/10/26 - Form 144
- 3/9/26 - Form 144
- OLMA's page on the SEC website